Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Quantum Biopharma (QNTM) Cash & Equivalents (2018 - 2025)

Quantum Biopharma's Cash & Equivalents history spans 8 years, with the latest figure at $1.9 million for Q4 2025.

  • On a quarterly basis, Cash & Equivalents fell 68.22% to $1.9 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.9 million, a 68.22% decrease, with the full-year FY2025 number at $1.9 million, down 68.22% from a year prior.
  • Cash & Equivalents hit $1.9 million in Q4 2025 for Quantum Biopharma, down from $6.0 million in the prior quarter.
  • Over the last five years, Cash & Equivalents for QNTM hit a ceiling of $39.3 million in Q3 2021 and a floor of $1.9 million in Q4 2025.
  • Historically, Cash & Equivalents has averaged $15.1 million across 5 years, with a median of $6.0 million in 2024.
  • Biggest five-year swings in Cash & Equivalents: skyrocketed 206.32% in 2021 and later crashed 89.69% in 2023.
  • Tracing QNTM's Cash & Equivalents over 5 years: stood at $35.3 million in 2021, then tumbled by 51.84% to $17.0 million in 2022, then plummeted by 78.6% to $3.6 million in 2023, then skyrocketed by 65.0% to $6.0 million in 2024, then crashed by 68.22% to $1.9 million in 2025.
  • Business Quant data shows Cash & Equivalents for QNTM at $1.9 million in Q4 2025, $6.0 million in Q3 2025, and $6.0 million in Q2 2025.